← FDA DRUG APPROVALS

FDA ANDA · ANDA200142

ACAMPROSATE CALCIUM

acamprosate calcium enteric-coated

Sponsor: MYLAN

APPLICATION
ANDA200142
TYPE
ANDA
ORIGINAL APPROVAL
2014-03-11
LATEST ACTION
2014-03-11
ROUTE
ORAL
DOSAGE FORM
TABLET, DELAYED RELEASE
MARKETING STATUS
Prescription

Products

ACAMPROSATE CALCIUMPrescription
ACAMPROSATE CALCIUM 333MG · TABLET, DELAYED RELEASE · ORAL

Approval history

2014-03-11UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →